Since 1992, Quantex has developed and executed methods for trace metals (metallic impurities) analysis employing modern quantitative technologies for drug and drug products. With previous knowledge and experience in trace metals analyses, our founders sought to equip Quantex’s labs with flame and graphite furnace atomic absorption (AAS), as well as inductively coupled plasma (ICP-AES & ICP-MS) capabilities. These capabilities were enhanced with one of the first commercial microwave digestion systems, a CEM MDS-81D.
Over the ensuing years, we have continued to expand upon these capabilities, our knowledge and experience. Today, our laboratories are equipped with state of the art, 5th generation high performance microwave digestion systems, AAS, ICP-AES and ICP-MS systems. These technologies provide both the capabilities and flexibility in meeting the challenges that varying matrices present in the quantitative analysis of trace metals.
Metallic impurities can originate from multiple sources. These sources include catalysts, raw materials used in the manufacture of the API and drug product, glassware, reactors, and equipment used in the storage and handling of starting materials, intermediates, reagents, water and container closure systems. For 25 years Quantex has been involved with developing and validating flame and graphite furnace atomic absorption, ICP-AES and ICP-MS methods used to assess the presence of metallic impurities in API, drug product, medical device, biological tissue, raw materials, and more. Our analytical team has a proven track record of developing methods for oral dosage forms, parenterals, ointments, creams, coated stents and implantables, as well as methods for OTC products.
Our scientists develop analytical methods that are robust, transferable, reproducible, and designed to support and meet regulatory requirements and submissions. Quantex’s method development services ensure that your team makes the best decisions and hits drug development,regulatory and QA milestones on time and on budget.
Our approach is to work closely with each client collaboratively, to fully understand both the requirements of the method and the nature of the drug, product, or device. Then, through our unique blend of experience, expertise, and focus we evaluate parameters and identify critical quality attributes. Supporting this are our state-of-the-art laboratories with multiple AAS, ICP and microwave digestion systems. This allows us to develop and validate methods that are robust, efficient, fit for purpose, and ranged properly.
FDA Registered & Inspected Strict Compliance with cGMP & GLP ISO 17025 Accredited
METHOD DEVELOPMENT SERVICES
25 years of experience developing and executing methods for trace metals analysis, using modern quantitative technology for for drug and drug products.
ISO 17025 accredited specifically for USP/ICH Elemental Impurities.
Expertise in troubleshooting complex sample matrices and method challenges.
Regulatory experience - asking the right questions to determine the most appropriate testing approach.
Pharmacopeia liaison with both USP and EP for clarification, and major industry compendial groups.
Focus on service that meets clients' needs-whether a non-GMP general screening method or a validated GMP analysis that will withstand regulatory review and scrutiny.
Comprehensive instrument capabilities and capacity for method development/validation and rapid turnaround time on routine analysis.
Multiple Milestone state of the art high performance closed vessel microwave digestion systems.
Multiple Hotblock type digestions systems for open vessel acid digestion.
Agilent 700 series high speed sequential Axial ICP-AES.
Perkin Elmer 5300DV dual view simultaneous ICP-AES with both radial and axial viewing.
Bruker 820 ICP-MS with 90 degree reflecting optics and 9 decade linearity.
Cetac U5000AT Ultrasonic nebulizer for use in extending ICP-AES and ICP-MS detection limits 10x lower.